Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing
Abstract
Multiple myeloma (MM) remains incurable despite major therapeutic advances, underscoring the unmet need for earlier and genetically informed intervention. The rationale for such intervention lies in the stepwise evolution of MM from precursor states, including monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), during which genetic alterations accumulate and drive the emergence, expansion, and evolution of malignant clones. In 2025, three landmark cohort studies using whole-exome or whole-genome sequencing (WES/WGS) proposed distinct but relevant genomic frameworks for reclassifying disease risk in MGUS and SMM. Despite differences in design and analyses, these frameworks converge on several principles: (i) the malignant genomic architecture of myeloma is established well before clinical progression; (ii) a substantial fraction of clinically defined precursor disease already harbors the hallmarks of overt myeloma; and (iii) WES/WGS-derived features meaningfully improve clinical risk models. In this perspective, we critically reviewed these three contemporaneous frameworks and synthesize their convergent implications, not previously consolidated for clinical use, into a practical approach toward genomics-guided management of myeloma precursor conditions.
Related
- Metagenomic Next-Generation Sequencing Enhances Pathogen Detection and Prognostic Stratification in Hematopoietic Stem Cell Transplantation Recipients.
- Biomarkers for risk stratification of malignancy-prone precancerous conditions: focusing on gastric intestinal metaplasia.
- Converging arboviral outbreaks demand disease-agnostic public health responses
- Nicotinamide Mononucleotide Is Associated with Attenuation of OGD/R-Induced Pro-Inflammatory Programs in Microglia: Transcriptomic Evidence Converging on the NLRP3 Inflammasome and Lipid-Droplet-Related Molecular Signatures
- From Amyloid Exposure to Genetic Causality: Converging hiPSC-Based Models of Alzheimer’s Disease
BibTeX
@article{xiong2026genomicsguided,
title = {{Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing}},
author = {Xinyi Xiong BS and Xuezhu Wang MD and Jian Li MD and Kaini Shen MD},
journal = {Technology in Cancer Research \& Treatment},
year = {2026},
month = oct,
doi = {10.1177/15330338261503783},
url = {https://doi.org/10.1177/15330338261503783},
note = {CC BY},
}
RIS
TY - JOUR
TI - Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing
AU - Xinyi Xiong BS
AU - Xuezhu Wang MD
AU - Jian Li MD
AU - Kaini Shen MD
PY - 2026
DA - 2026/10/01
JO - Technology in Cancer Research & Treatment
DO - 10.1177/15330338261503783
UR - https://doi.org/10.1177/15330338261503783
AB - Multiple myeloma (MM) remains incurable despite major therapeutic advances, underscoring the unmet need for earlier and genetically informed intervention. The rationale for such intervention lies in the stepwise evolution of MM from precursor states, including monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), during which genetic alterations accumulate and drive the emergence, expansion, and evolution of malignant clones. In 2025, three landmark cohort studies using whole-exome or whole-genome sequencing (WES/WGS) proposed distinct but relevant genomic frameworks for reclassifying disease risk in MGUS and SMM. Despite differences in design and analyses, these frameworks converge on several principles: (i) the malignant genomic architecture of myeloma is established well before clinical progression; (ii) a substantial fraction of clinically defined precursor disease already harbors the hallmarks of overt myeloma; and (iii) WES/WGS-derived features meaningfully improve clinical risk models. In this perspective, we critically reviewed these three contemporaneous frameworks and synthesize their convergent implications, not previously consolidated for clinical use, into a practical approach toward genomics-guided management of myeloma precursor conditions.
SN - 1533-0338
SN - 1533-0346
ER -